spacer
home > ebr > winter 2003 > capturing recombinant proteins
PUBLICATIONS
European Biopharmaceutical Review

Capturing Recombinant Proteins

Recombinant DNA technologies are widely used in the drug discovery process, not only to produce novel, engineered proteins, but also to generate proteins in the quantities required for downstream research. Purifying these proteins remains a bottleneck. This article looks at a novel method to rapidly isolate structurally and functionally intact histidine-tagged recombinant proteins using superparamagnetic beads.

Recombinant DNA (rDNA) technologies are a cornerstone of the biotechnology industry and have revolutionised approaches to the discovery of new medicines. Pioneered by scientists such as Paul Berg, Stanley Cohen and Herbert Boyer in the early 1970s, rDNA methodologies allow scientists to 'cut and paste' DNA to engineer novel proteins, and to transfer DNA from one organism to another. They also provide the means to generate proteins in the quantities required for downstream studies in drug discovery - from target identification, target validation and screening of compound libraries, to ADME-Tox studies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Beate Rygg Johnsen, Product Manager at Dynal Biotech

Beate Rygg Johnsen is an International Product Manager at Dynal Biotech, Oslo in Norway and is responsible for the company's efforts within the area of proteomics. Beate is driving Dynal Biotech's penetration in drug discovery. She holds a MSc and a Cand Scienct from the University of Oslo, Institute of Biochemistry, and a degree in marketing management from BI, Norwegian School of Management.

spacer
Beate Rygg Johnsen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new market reference added to Safe’n’Sound®, our passive safety device platform

Safe’n’Sound® is on the market in Europe with a newly registered injectable medication. The commercial launch of HULIO™ (Adalimumab Biosimilar) was initiated in selected European markets on October 19,2018. Hulio™, developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. is approved as a biosimilar for the same indications as the reference product, Humira®.
More info >>

White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). It’s about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement